First quarter 2001 net loss down 73.6% to $7.9 mil. while sales jump 21.9% to $12.8 mil. compared to year-ago quarter, company announces during May 15 analysts call. President/CEO Fred Toney says health products retailer should break even in 2002 as it has reached a private debt refinancing agreement worth roughly $3.4 mil. Healthcentral also has scheduled a May 31 NASDAQ hearing to approve 1-for-50 reverse stock split to keep company listed
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
FDA employees are concerned that while the budget authority total proposed for fiscal year 2026 meets the user free appropriations' triggers, the FDA could have trouble meeting allocation triggers without cuts to non-review work.
The suits are an early test of the Arkansas law banning company ownership of PBMs and pharmacies in the state, as other states consider similar legislation.
An unintended consequence of a provision framed as an administrative change in the bill could significantly reduce medication adherence among low-income older adults and increase mortality, a study found.